SEC Form 4 · accession 0001179110-17-000240
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Dec 30, 2016
Accepted (ET)
Jan 4, 2017 · 4:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 30, 2016 | M | 26,178 | $2.10 | A | 90,227 | D | |
| Common StockF2 | Dec 30, 2016 | S | 23,244 | $2.55 | D | 66,983 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.10 | Dec 30, 2016 | M | 26,178 | D | — | Feb 1, 2017 | Common Stock | 26,178 | 0 | D |
Explanation of responses
- F1Includes 1,051 and 1,450 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2016 and December 15, 2016, respectively.
- F2Represents the sale of 23,244 shares in multiple transactions, ranging in price from $2.52 to $2.61 per share, resulting in a weighted average sale price per share of $2.55. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. Shares were sold to cover the option exercise price and to satisfy the tax withholding obligation.
- F3The option is fully vested and immediately exercisable.